Braidwell LP Acquires Shares of 50,000 Heartflow, Inc. $HTFL

Braidwell LP purchased a new position in Heartflow, Inc. (NASDAQ:HTFL) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 50,000 shares of the company’s stock, valued at approximately $1,683,000. Braidwell LP owned approximately 0.06% of Heartflow at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of HTFL. TFC Financial Management Inc. bought a new position in shares of Heartflow during the third quarter valued at approximately $40,000. Legal & General Group Plc bought a new stake in shares of Heartflow in the 3rd quarter worth approximately $59,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Heartflow in the 3rd quarter worth approximately $234,000. Legato Capital Management LLC purchased a new stake in shares of Heartflow in the 3rd quarter worth approximately $243,000. Finally, Sandia Investment Management LP bought a new position in Heartflow during the 3rd quarter valued at approximately $252,000.

Heartflow Trading Down 1.4%

HTFL stock opened at $20.49 on Friday. The stock’s 50 day simple moving average is $27.66 and its 200 day simple moving average is $30.69. Heartflow, Inc. has a 12-month low of $20.13 and a 12-month high of $41.22. The stock has a market capitalization of $1.74 billion and a PE ratio of -11.32.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on HTFL. Weiss Ratings reissued a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th. Canaccord Genuity Group reiterated a “buy” rating and issued a $40.00 price target on shares of Heartflow in a research note on Monday, March 9th. Finally, Wells Fargo & Company assumed coverage on shares of Heartflow in a research report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $38.50.

Insider Buying and Selling at Heartflow

In other news, Director Jeffrey C. Lightcap acquired 40,000 shares of Heartflow stock in a transaction that occurred on Tuesday, December 16th. The stock was bought at an average price of $26.34 per share, for a total transaction of $1,053,600.00. Following the completion of the transaction, the director owned 40,000 shares in the company, valued at $1,053,600. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Julie A. Cullivan sold 9,122 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $25.00, for a total value of $228,050.00. Following the completion of the transaction, the director directly owned 27,291 shares in the company, valued at approximately $682,275. This represents a 25.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 2,117,674 shares of company stock worth $59,052,646.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.